ochratoxin a has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Erviti, L; Alvarez-Herrera, N; Blesa, J; Cooper, JM; de Toro, M; Forcen, R; Gonzalez-Peñas, E; Izco, M; Lopez de Cerain, A; Vettorazzi, A | 1 |
| Alvarez-Erviti, L; Arce-López, B; De Santis, B; Debegnach, F; González-Peñas, E; Izco, M; Lizarraga, E; López de Cerain, A; López-Calvo, S; Marzo-Sola, ME; Vettorazzi, A | 1 |
2 other study(ies) available for ochratoxin a and Parkinson Disease
| Article | Year |
|---|---|
Oral subchronic exposure to the mycotoxin ochratoxin A induces key pathological features of Parkinson's disease in mice six months after the end of the treatment.
Topics: Administration, Oral; alpha-Synuclein; Animals; Dopaminergic Neurons; Intestinal Mucosa; Lysosomal-Associated Membrane Protein 2; Male; Mesencephalon; Mice, Inbred BALB C; MicroRNAs; Mycotoxins; Ochratoxins; Parkinson Disease; Pars Compacta; Phosphorylation; Time Factors | 2021 |
Biomonitoring of Mycotoxins in Plasma of Patients with Alzheimer's and Parkinson's Disease.
Topics: Alzheimer Disease; Biological Monitoring; Chromatography, Liquid; Humans; Mycotoxins; Neurodegenerative Diseases; Ochratoxins; Parkinson Disease; Sterigmatocystin; Tandem Mass Spectrometry; Trichothecenes; Zearalenone | 2021 |